Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCCAM Investigator-Initiated Funding Increases On Horizon - Straus

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary & Alternative Medicine will step up support for investigator-initiated research next fiscal year, NCCAM Director Stephen Straus, MD, told the center's advisory council at a meeting in Rockville, Md. Jan. 24-25.

You may also be interested in...



NCCAM Intramural Research Program Outlined In Strategic Plan

A continued commitment to sponsoring clinical research on complementary and alternative medicine and the creation of an intramural program at NIH are two central goals highlighted in the National Center for Complementary & Alternative Medicine's draft five-year strategic plan released May 10.

NCCAM Intramural Research Program Outlined In Strategic Plan

A continued commitment to sponsoring clinical research on complementary and alternative medicine and the creation of an intramural program at NIH are two central goals highlighted in the National Center for Complementary & Alternative Medicine's draft five-year strategic plan released May 10.

NCCAM Intramural Research Program Outlined In Strategic Plan

A continued commitment to sponsoring clinical research on complementary and alternative medicine and the creation of an intramural program at NIH are two central goals highlighted in the National Center for Complementary & Alternative Medicine's draft five-year strategic plan released May 10.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel